PMV Pharmaceuticals Inc(PMVP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.41 | Insider Own | 6.9% | Shs Outstand | 75.5M | Perf Week | 3.45% |
| Market Cap | 0.10B | Forward P/E | - | EPS next Y | 25.1% | Insider Trans | - | Shs Float | 70.3M | Perf Month | -19.16% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.34 | Inst Own | 41.94% | Short Float | 3.25% | Perf Quarter | 21.62% |
| Income | -0.08B | P/S | - | EPS this Y | 19.26% | Inst Trans | -3.72% | Short Ratio | 3.42 | Perf Half Y | -2.88% |
| Sales | 0.00B | P/B | 1.01 | EPS next 5Y | 21.53% | ROA | -64.04% | Short Interest | 2.29M | Perf YTD | 8% |
| Book/sh | 1.34 | P/C | 1.28 | EPS past 3/5Y | 2.74% -13.98% | ROE | -70.93% | 52W High | -29.32% ($1.91) | Perf Year | -4.93% |
| Cash/sh | 1.05 | P/FCF | - | Sales past 3/5Y | - | ROIC | -105.2% | 52W Low | 32.35% ($1.02) | Perf 3Y | 9.76% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 9.38% | Gross Margin | - | Volatility(W/M) | 10.41% 9.64% | Perf 5Y | -94.28% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.12 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.7 | EPS Q/Q | 16.92% | Profit Margin | - | RSI (14) | 49.4 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.7 | Sales Q/Q | - | SMA20 | -3.16% ($1.39) | Beta | 1.49 | Target Price | $4.2 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/14 | SMA50 | -2.42% ($1.38) | Rel Volume | 0.36 | Prev Close | $1.38 |
| Employees | 54 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 12.26% - | SMA200 | 3.84% ($1.3) | Avg Volume(3M) | 0.67M | Price | $1.35 |
| IPO | 2020/9/25 | Option/Short | Yes/Yes | Trades | 955 | Volume | 238,115 | Change | -2.17% |
🧬 A US clinical-stage biotech company developing innovative precision oncology drugs that reactivate p53, the 'Achilles' heel' of cancer cells. Through its proprietary 'rezatapopt', the company is establishing a new standard of care for patients with treatment-resistant ovarian cancer and solid tumors.
Over the past 1 year, roughly in the middle
29% below its 1-year high.
Traded less than usual. That is 36% of its average volume.
PMVP has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +19.3% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -94.3%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 41.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #360 of 594 in the industry
Based on market cap of $102M.
CBUS#357 Cibus Inc $103M PER - 
VANI#358 Vivani Medical Inc $103M PER - 
ENGN#359 enGene Therapeutics Inc $103M PER - PMVP#360 PMV Pharmaceuticals Inc $102M PER - 
KZIA#361 Kazia Therapeutics Limited ADR $100M PER - 
FAQ
What kind of company is PMVP?
PMVP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PMVP?
The market cap of PMVP is approximately $102M, ranking 4,470 within its sector.
What is the 52-week high and low for PMVP?
PMVP has recorded a 52-week high of $1.91 and a low of $1.02.
